We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI-Enhanced Platform Detects Cardiac Amyloidosis by Assessing Single Echocardiogram

By MedImaging International staff writers
Posted on 27 Apr 2023
Print article
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)

Cardiac amyloidosis, a condition resulting from abnormal protein deposits in heart tissue, is a diverse disease that can be challenging to diagnose, often necessitating specialized expertise and testing. The disease is categorized based on the specific protein involved, with the primary subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by the misfolding of the transthyretin protein, and a less common form called light chain amyloidosis (AL cardiac amyloidosis), caused by the buildup of immunoglobulin light chains. Now, an AI-powered platform can detect cardiac amyloidosis by analyzing echocardiograms and using just one commonly acquired ultrasound view of the heart.

The platform, EchoGo Amyloidosis, from Ultromics (Oxford, UK) utilizes AI technology to address the unmet need for early diagnosis of amyloidosis patients, who might otherwise remain undiagnosed until the disease has progressed, delaying treatment and negatively affecting patient outcomes. Developed in collaboration with multiple leading clinical partners, EchoGo Amyloidosis is designed as a module within Ultromics' EchoGo Platform and has received FDA Breakthrough Device Status. This FDA Breakthrough Device Designation represents a significant advancement for amyloidosis patients, who face a bleak five-year mortality rate of 44%-65% after diagnosis if the condition is not detected early enough.

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients."

Related Links:
Ultromics 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
PACS Workstation
CHILI Web Viewer
New
Pre-Op Planning Solution
Sectra 3D Trauma
New
Compact C-Arm
Arcovis DRF-C S21

Print article

Channels

MRI

view channel
Image: Diamond dust offers a potential alternative to the widely used contrast agent gadolinium in MRI (Photo courtesy of Max Planck Institute)

Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans

Gadolinium, a heavy metal used for over three decades as a contrast agent in medical imaging, enhances the clarity of MRI scans by highlighting affected areas. Despite its utility, gadolinium not only... Read more

Nuclear Medicine

view channel
Image: The multi-spectral optoacoustic tomography (MSOT) machine generates images of biological tissues (Photo courtesy of University of Missouri)

New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure

Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.